|
| ■ Partnerships |
|
In addition to our internal research, development and clinical activities, MBRI
is actively pursuing collaborations with leading companies, institutes, and academic institutions
in the fields of pharmaceutics, biotechnology, biochemical engineering and medicinal chemistry.
Development and Commercialization
MBRI has been operating in particular position between academia and industries. The successful
collaboration is a key feature of MBRI' strategy for commercializing our product candidates and
technologies. To this end, MBRI seeks collaborations to advance the development and commercialization
of our own product candidates. Green Cross is one of our principal corporate collaborations.
Research Collaborations
To maximize the value of proprietary technologies and knowledge, MBRI seeks strategic partnerships.
MBRI has formed a range of partnerships to access therapeutic targets, candidates, and innovative
technologies. These partnerships have been with companies, research institutes and universities.
• Green Cross Central Research Institute
• Green Cross Reference Laboratory
• Fraunhofer Institute for Molecular Biology and Ecology
• ID Gene
• National Cancer Center
• Korea Research Institute of Bioscience and Biotechnology
• Korea Research Institute of Chemical Technology
• Seoul National University
• POSTECH
• Chungnam National University
• Chonbuk National University
• Yonsei University
• Ajou University
• Hanyang University
WHO Collaborating Centre for Research and
Development of Vaccines and Diagnostic Reagents
Since MBRI was designated as a WHO Collaborating Centre for Research and Development of Vaccines
and Diagnostic Reagents in 1989, MBRI has made continuous efforts on research and development in
order to fight against emerging infectious diseases along with WHO as a WHO Collaborating Centre.
The terms of reference for the Centre are;
• To participate in collaborative studies with WHO on the research and development of
new vaccines and diagnostic reagents,
• To provide consulting services on the development and quality control of vaccine and diagnostic
reagents,
• To provide training for fellow who are developing vaccines and diagnostic reagents,
• To provide reference for vaccines and diagnostic reagents, and
• To collect and disseminate information on the development of vaccines and
diagnostic reagents.
Currently MBRI is extending its efforts from conventional type prophylactic vaccines to therapeutic
vaccines including DNA vaccine and CTL based immunotherapeutic for hepatitis C. In the field of
developing diagnostic reagents, MBRI has succeeded in developing the SARS-CoV-specific RNA detection
kit using real-time RT-PCR technology. Since no licensed drug or vaccine is currently available to
treat SARS, it is exceedingly important to develop new technologies that will allow for the rapid
and simple diagnosis of SARS, in order to curtail the spread of the virus. With other available
technologies such as lab-on-a-chip as well as the established real-time RT-PCR technique, MBRI is
now in the process of developing molecular diagnostic technologies against life-threatening diseases
such as HIV and hepatitis. We firmly believe that these diagnostics will play crucial roles in monitoring
the safety of blood supplies, in the near future, will be further applied to the other fields such as
veterinary, forensic, military and food science. More detail information about our recent activities as
a WHO Collaborating Centre are available from the following documents.
Download Adobe Reader ☞
Research Grant
• Green Cross Corporation
• Ministry of Science & Technology
• Ministry of Commerce, Industry & Energy
• Ministry of Health & Welfare
MBRI is interested in discussing potential collaborations and is open to any proposal that provides
mutual benefit. Scientists wishing to contact MBRI research staff for collaboration in any field are
welcome to send inquires to mogam@mogam.re.kr or
mogaminst@greencross.com.
|
|
|
